117P Immune checkpoint inhibitors (ICI) in combination with chemotherapy as first-line (1L) treatment for non-small cell lung cancer (NSCLC): A pair-wise meta-analysis (MA)
ConclusionThe association of immunotherapy plus CH is a better treatment option for all patients in 1L NSCLC. Standard subgroups are the most benefited, except liver mx patients and EGFR/ALK+ especially benefited for the combination of an antiPD-L1 and an antiVEGF. Table:117P OS by subgroupsHR (CI 95%)Women0.51 [0.32-0.84]Men0.75 [0.64-0.87]<650.62 [0.46-0.84] ≥650.74 [0.63-0.87]PS 00.65 [0.49-0.88]PS 10.72 [0.60-0.87]Never smoker0.47 [0.26-0.85]Smoker0.71 [0.56-0.91]No liver mx0.61 [0.55-0.67]Liver mx0.69 [0.46-1.0]PD-L1 H0.66 [0.52-0.82]Legal entity responsible for the studyThe authors.FundingRoche Farma S.A.Discl...
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
56P Predictive factors of intensive care outcomes of patients admitted with immune-related adverse events
ConclusionIt is likely that the number of critical care admissions may increase with more patients receiving ICPI. These events can be responsible for great morbidity which might be associated with increased mortality. IB such as high LDH, high NLR and high SIRI might correlate to poor outcome and worse survival and could be used to develop awareness of these events and a more effective approach. However, some of these results were not statistically significant and further studies are needed with a larger data to validate them.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureA...
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
22P Early changes in plasma cell-free DNA (cfDNA) as a predictive biomarker of immune checkpoint inhibitors (ICIs) efficacy
ConclusionThe monitoring of early changes of cfDNA levels is a fast approach to predict response to ICI therapy in our cohort. Further validation of these results and correlation with circulating tumor DNA is ongoing.Legal entity responsible for the studyThe authors.FundingThis research has been partially funded by the Comprehensive Program of Cancer Immunotherapy& Immunology (CAIMI), supported by the Banco Bilbao Vizcaya Argentaria Foundation (BBVA Foundation) - Grant 9/2017.DisclosureC. Hierro Carbo: Research grant / Funding (self): Bayer; Honoraria (self): Ignyta; Honoraria (self), Travel / Accommodation / Expenses:...
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
164P Combined detection of CD137 and type 1 functions improves identification and characterization of the activated T lymphocyte repertoire
ConclusionCombined detection of CD137 and common type 1 functions represents a more comprehensive method to identify and characterize the total repertoire of tumor-antigen specific, activated T lymphocytes, regardless of the antigen recognized.Legal entity responsible for the studyHerlev and Gentofte Hospital.FundingResearch grant A11806 and A12535, The Danish Cancer Society; Research grant R233-2016-3728 and R286-2018-991 Lundbeck Foundation; Clinician-Scientist Grant from the Herlev and Gentofte Hospital Research Council.DisclosureAll authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
134P Comprehensive assessment of anti-tumour PDL1 blockade effect in a sarcoma mouse model
ConclusionAltogether, this multiparametric dataset gives i) a better understanding of intrinsic features of the preclinical model and deeper insights into the mechanism of action of an effective drug, and ii) might serve as a platform combination-based strategy for comprehensive explorations of novel candidates.Legal entity responsible for the studyAlban Bessede.FundingExplicyte Immuno-Oncology.DisclosureA. Bessede: Shareholder / Stockholder / Stock options, Full / Part-time employment: Explicyte. All other authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
7P Multispectral immunofluorescence and computational imaging analysis define the prognostic role of T-cell infiltrates in gastric cancer
ConclusionThis study identified and validated CD45RO and FOXP3 T cell infiltrates as independent prognostic markers in Western GC patients. This may enable personalized follow up or (neo)adjuvant treatment strategies. Whether high infiltrates are predictive of immunotherapy benefit should be assessed. Unexpectedly, high FOXP3 densities were associated with longer CSS, warranting studies into the role regulatory T cells in GC.Legal entity responsible for the studyMarco Gerlinger.FundingNational Institute for Health Research and Biomedical Research Council - Royal Marsden Hospital, Cancer Research UK, Schottlander Foundation...
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
149P Revamping the ovarian tumour microenvironment with an oncolytic adenovirus yields enhanced tumour-infiltrating lymphocyte anti-tumour activity
ConclusionThese data illustrate the potential of oncolytic adenovirus coding for TNFa and IL-2 to rewire the ovarian tumour microenvironment for effective TIL anti-tumour reactivity. This approach may improve the efficacy of adoptive TIL therapy in ovarian cancer patients, thus warranting further clinical investigation.Legal entity responsible for the studyTILT Biotherapeutics Ltd.FundingTILT Biotherapeutics Ltd.DisclosureJ.M. Santos: Full / Part-time employment: TILT Biotherapeutics Ltd. V. Cervera-Carrascon: Full / Part-time employment: TILT Biotherapeutics Ltd. M. Siurala: Full / Part-time employment: TILT Biotherapeuti...
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
118P The role of asunercept as a selective CD95L inhibitor in cutaneous melanoma: Rationale and results from an enhanced TiRP model
ConclusionSelective CD95L inhibition by asunercept might have potential clinical implications in different tumours beyond recurrent glioblastoma, including cutaneous melanoma. To date, asunercept has demonstrated clinical efficacy and safety in patients with recurrent glioblastoma and myelodysplastic syndromesand may warrant further investigation in clinical trials.Legal entity responsible for the studyThe authors.FundingApogenix AG.DisclosureA. Krendyukov: Full / Part-time employment: Apogenix AG. N. Kneisel: Full / Part-time employment: Apogenix AG. J. Zhu: Research grant / Funding (self), Full / Part-time employment: Lu...
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
57P Immune-related adverse events: The experience of a community hospital
ConclusionThe data we present here represents an heterogeneous population in real world settings and it similar to the literature. Implementing careful follow-up for immune related events contributes to promptly diagnose and treat.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
100P Combination of intratumoural double-stranded RNA (dsRNA) BO-112 with systemic anti-PD-1 in patients with anti-PD-1 refractory cancer
ConclusionBO-112 combined with anti PD-1 shows a manageable safety profile, direct antitumor effects and innate and adaptive immune system activation. Efficacy analyses suggest potential to reverse primary resistance to anti-PD1 treatment. Studies in other indications, including combination with radiotherapy, are planned.Clinical trial identificationNCT02828098.Legal entity responsible for the studyBioncotech Therapeutics.FundingBioncotech Therapeutics.DisclosureI. Marquez-Rodas: Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Bristol-Myers Squibb; Advisory / Consultancy, ...
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
75P Immune-related toxicities in NSCLC: Real-world experience from a tertiary cancer center
ConclusionIn our large real-world retrospective cohort study the incidence of irAEs reflected that seen in clinical trials. There appears to be a toxicity-efficacy relationship with irAEs; however, larger studies are required to validate this.Legal entity responsible for the studyThe Clatterbridge Cancer Centre NHS Foundation Trust.FundingHas not received any funding.DisclosureA.C. Olsson-Brown: Honoraria (self): MSD; Honoraria (self), Research grant / Funding (self): Roche; Honoraria (self), Advisory / Consultancy: Bristol-Myers Squibb; Research grant / Funding (self): Eli Lily; Research grant / Funding (self): Novartis. ...
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
23P Immunological signature meta-analysis across lung cancer cohorts within the NanoString Clinical Transcriptional Atlas Group (CTAG) associated with patient outcome and history
ConclusionThis multi-cohort study allows for the development of multi-variate predictors of response to anti-PD1 monotherapy using a single research assay to transcriptionally profile the tumors. We can generate robust predictions from real-world cohorts, which may lead to the development of improved diagnostic assays to guide treatment decisions.Legal entity responsible for the studyNanoString Technologies.FundingNanoString Technologies.DisclosureN. Radosevic-Robin: Research grant / Funding (institution): NanoString Technologies. J. Reeves: Full / Part-time employment: NanoString Technologies. K. Leroy: Research grant / F...
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
165P Pre-therapeutic evaluation of patient-specific responses to immune-checkpoint inhibition in colorectal cancer
ConclusionIn vitro testing of individual responses to CPIs will be of key relevance for stratifying pre-treated pMMR/MSS CRC patients according to their likelihood to benefit from IO therapy and holds the potential to make these powerful drugs available to more patients suffering from CRC.Legal entity responsible for the studyThe authors.Funding2cureX, BMBF KMU-innovativ.DisclosureT. Sturmheit: Full / Part-time employment: 2cureX. T. Sutus Temovski: Full / Part-time employment: 2cureX. J. Thastrup: Full / Part-time employment: 2cureX. W. Fiedler: Advisory / Consultancy, Research grant / Funding (self), Licensing / Royaltie...
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
135P Analysis of the immune microenvironment in pre-treatment non-small cell lung cancer (NSCLC) patients with follow-up response data to second-line immunotherapy
ConclusionTaken together these data demonstrate that despite various lines of previous radiotherapy and chemotherapy spanning several years, immune profiles associated with response to second-line immunotherapy can be detected in surgical first-line resection samples.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureM. Bhagat: Shareholder / Stockholder / Stock options, Officer / Board of Directors: TriStar Technolgoy Group. All other authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
8P The prognostic value of tumour-infiltrating lymphocytes (TILs) in pancreatic cancer: A systematic review and meta-analysis
ConclusionHigh infiltration of CD3+ and CD8+ lymphocytes is associated with improved OS among patients with resected PC, whereas high infiltration of FoxP3+ T cells is associated with decreased OS. CD4+ and CD20+ lymphocytes did not have a significant impact on OS. Based on these findings, staining for TILs, especially CD3+, CD8+ and FoxP3+ T cells, might be an important tool for future assessment of patient survival and prognosis, as well as for tailored oncological therapy.Clinical trial identificationCRD42019134744.Legal entity responsible for the studyThe authors.FundingCenter for Surgical Science.DisclosureAll authors...
Source: Annals of Oncology - December 15, 2019 Category: Cancer & Oncology Source Type: research
